1. Thomas C. Westfall and David P. Westfall. Adrenergic agonist and antagonists. Goodman & Gilman’s: The Pharmacological basics of therapeutics. 12th Edition. New York Mc Graw Hill Medical 2011. Page – 295.
2. Gerald G. Briggs and Roger K. Freeman. M. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 2572-2573.
3. Shire. Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on January 2019] [Accessed 29th October 2020] https://clinicaltrials.gov/ct2/show/NCT01518946
4. William Smith, Hong Wan, David Much, Antoine G. Robinson and Patrick Martin. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. NCBI; PMC National Library of Medicine, National Institute of Health. July 2016. [Accessed 29th October 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951503/
5. Specifar S.A. Electronic Medicines Compendium (EMC); [Revised on November 2019] [Accessed 29th October 2020] https://www.medicines.org.uk/emc/files/pil.9703.pdf
6. Cross Vetpharm Group UK Limited. Electronic Medicines Compendium (EMC); [Revised on October 2018] [Accessed 29th October 2020] https://www.medicines.org.uk/emc/files/pil.2265.pdf
7. AA Pharma Inc. [Revised on July 2010] [Accessed 29th October 2020] https://www.aapharma.ca/downloads/en/PIL/Midodrine_PM.pdf
8. Takeda GmbH. Health Products Regulatory Authority. [Revised on August 2017] [Accessed 29th October 2020] https://www.hpra.ie/img/uploaded/swedocuments/2194041.PPA1097_026_001.64e73382-899e-493a-aad9-add1300c970e.000001Product%20Leaflet%20Approved.170825.pdf